Back to results
US 8,709,429 B2Granted
Markers of acute myeloid leukemia stem cells
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsRavindra Majeti, Irving L. Weissman
Life of this patent
Estimating the term…
Abstract
Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
Claims12
A method of targeting or depleting acute myeloid leukemia cancer stem cells (AMLSC), the method comprising:
- contacting blood cells of a human suffering from acute myeloid leukemia with an antibody that specifically binds CD99 in order to target or deplete AMLSC.
A method of targeting or depleting acute myeloid leukemia cancer stem cells (AMLSC), the method comprising:
- contacting blood cells of a human suffering from acute myeloid leukemia with an antibody that specifically binds TIM3 in order to target or deplete AMLSC.
Dependencies are inferred from the claim text.